900 related articles for article (PubMed ID: 21228259)
21. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.
Kristiansen K
Pharmacol Ther; 2004 Jul; 103(1):21-80. PubMed ID: 15251227
[TBL] [Abstract][Full Text] [Related]
22. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.
Johnson MP; Nisenbaum ES; Large TH; Emkey R; Baez M; Kingston AE
Biochem Soc Trans; 2004 Nov; 32(Pt 5):881-7. PubMed ID: 15494040
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties.
Urwyler S; Gjoni T; Koljatić J; Dupuis DS
Neuropharmacology; 2005 Mar; 48(3):343-53. PubMed ID: 15721166
[TBL] [Abstract][Full Text] [Related]
24. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
Valant C; Felder CC; Sexton PM; Christopoulos A
Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
[TBL] [Abstract][Full Text] [Related]
25. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.
Antony J; Kellershohn K; Mohr-Andrä M; Kebig A; Prilla S; Muth M; Heller E; Disingrini T; Dallanoce C; Bertoni S; Schrobang J; Tränkle C; Kostenis E; Christopoulos A; Höltje HD; Barocelli E; De Amici M; Holzgrabe U; Mohr K
FASEB J; 2009 Feb; 23(2):442-50. PubMed ID: 18842964
[TBL] [Abstract][Full Text] [Related]
26. Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function.
Galvez T; Duthey B; Kniazeff J; Blahos J; Rovelli G; Bettler B; Prézeau L; Pin JP
EMBO J; 2001 May; 20(9):2152-9. PubMed ID: 11331581
[TBL] [Abstract][Full Text] [Related]
27. Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development.
Müller CE; Schiedel AC; Baqi Y
Pharmacol Ther; 2012 Sep; 135(3):292-315. PubMed ID: 22728155
[TBL] [Abstract][Full Text] [Related]
28. [G-protein-coupled receptors targeting: the allosteric approach].
Sebag JA; Pantel J
Med Sci (Paris); 2012 Oct; 28(10):845-51. PubMed ID: 23067415
[TBL] [Abstract][Full Text] [Related]
29. Tas1R1-Tas1R3 taste receptor variants in human fungiform papillae.
Raliou M; Boucher Y; Wiencis A; Bézirard V; Pernollet JC; Trotier D; Faurion A; Montmayeur JP
Neurosci Lett; 2009 Feb; 451(3):217-21. PubMed ID: 19146926
[TBL] [Abstract][Full Text] [Related]
30. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
Wang CI; Lewis RJ
Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
[TBL] [Abstract][Full Text] [Related]
31. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
Valant C; Sexton PM; Christopoulos A
Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
[TBL] [Abstract][Full Text] [Related]
32. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients.
Wellendorph P; Johansen LD; Bräuner-Osborne H
Mol Pharmacol; 2009 Sep; 76(3):453-65. PubMed ID: 19487246
[TBL] [Abstract][Full Text] [Related]
33. Molecular insights into allosteric modulation of Class C G protein-coupled receptors.
Leach K; Gregory KJ
Pharmacol Res; 2017 Feb; 116():105-118. PubMed ID: 27965032
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors.
Hoare SR
Drug Discov Today; 2005 Mar; 10(6):417-27. PubMed ID: 15808821
[TBL] [Abstract][Full Text] [Related]
35. New concepts in drug discovery: collateral efficacy and permissive antagonism.
Kenakin T
Nat Rev Drug Discov; 2005 Nov; 4(11):919-27. PubMed ID: 16264435
[TBL] [Abstract][Full Text] [Related]
36. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
Kenakin T
Trends Pharmacol Sci; 2007 Aug; 28(8):407-15. PubMed ID: 17629960
[TBL] [Abstract][Full Text] [Related]
37. Identifying novel modulators of G protein-coupled receptors via interaction at allosteric sites.
Presland J
Curr Opin Drug Discov Devel; 2005 Sep; 8(5):567-76. PubMed ID: 16159018
[TBL] [Abstract][Full Text] [Related]
38. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance.
Bosier B; Hermans E
Trends Pharmacol Sci; 2007 Aug; 28(8):438-46. PubMed ID: 17629964
[TBL] [Abstract][Full Text] [Related]
39. Dimers and beyond: The functional puzzles of class C GPCRs.
Kniazeff J; Prézeau L; Rondard P; Pin JP; Goudet C
Pharmacol Ther; 2011 Apr; 130(1):9-25. PubMed ID: 21256155
[TBL] [Abstract][Full Text] [Related]
40. Discovery and characterization of orthosteric and allosteric muscarinic M2 acetylcholine receptor ligands by affinity selection-mass spectrometry.
Whitehurst CE; Nazef N; Annis DA; Hou Y; Murphy DM; Spacciapoli P; Yao Z; Ziebell MR; Cheng CC; Shipps GW; Felsch JS; Lau D; Nash HM
J Biomol Screen; 2006 Mar; 11(2):194-207. PubMed ID: 16490772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
